Skip to main content

Table 1 Unadjusted associations for mortality or post-infection length of stay among patients with MRSA pneumonia

From: Association between microbial characteristics and poor outcomes among patients with methicillin-resistant Staphylococcus aureus pneumonia: a retrospective cohort study

 

Proportion of patients with characteristic

30-Day-In-Hospital mortalitya

Post-infection length of stayb

Characteristics

Patients who died N = 18

Patients who survived N = 57

Hazards ratio (95 % Confidence Interval)

P-value

Odds ratio (95 % Confidence Interval)

P-value

Patient characteristics

 Gender: Female

9 (50 %)

20 (35 %)

1.81 (0.72–4.57)

0.201

1.44 (0.63–3.30)

0.385

 Age ≥55 years

  

4.69 (1.36–16.22)

0.015

2.15 (0.95–4.87)

0.068

 Hospital admission within previous 12 months

6 (33 %)

31 (54 %)

0.52 (0.19–1.37)

0.185

0.40 (0.17–0.91)

0.028

 Previous MRSA infection or colonization

6 (33 %)

11 (19 %)

1.82 (0.68–4.88)

0.234

1.31 (0.50–3.42)

0.583

 Positive influenza test

2 (11 %)

3 (5 %)

1.69 (0.39–7.38)

0.488

2.13 (0.41–11.01)

0.368

 Charlson comorbidity index score- median (IQR)

2 (1–3)

2 (1–4)

0.99 (0.83–1.20)

0.948

0.99 (0.84–1.16)

0.896

Hospital-acquired infection

6 (33 %)

19 (33 %)

0.85 (0.32–2.29)

0.752

1.50 (0.64–3.53)

0.354

Antimicrobial prescribed

 Linezolid

2 (11 %)

12 (21 %)

0.60 (0.14–2.60)

0.492

0.36 (0.13–1.03)

0.056

 Vancomycin

17 (94 %)

54 (95 %)

0.61 (0.08–4.68)

0.223

3.10 (0.51–19.02)

0.221

 Both linezolid and vancomycin

1 (6 %)

9 (16 %)

0.37 (0.05–2.76)

0.331

0.43 (0.13–1.41)

0.162

Microbial characteristics

 Panton-Valentine leukocidin

5 (28 %)

24 (42 %)

0.82 (0.36–1.88)

0.645

0.82 (0.36–1.88)

0.645

 SCCmec

  Type II

12 (67 %)

27 (47 %)

1.22 (0.54–2.72)

0.634

1.22 (0.54–2.72)

0.634

  Type IV

6 (33 %)

29 (51 %)

0.79 (0.35–1.76)

0.555

0.79 (0.35–1.76)

0.555

  agr dysfunction

4 (22 %)

9 (16 %)

1.35 (0.44–4.10)

0.598

1.59 (0.54–4.62)

0.399

 Arginine catabolic mobile element

3 (17 %)

22 (39 %)

0.35 (0.10–1.20)

0.094

0.70 (0.30–1.64)

0.413

 Toxic shock syndrome toxin-1

1 (6 %)

2 (4 %)

1.22 (0.16–9.19)

0.846

2.35 (0.29–19.27)

0.423

 PFGE type

  USA100

11 (61 %)

25 (44 %)

1.87 (0.72–4.82)

0.197

1.20 (0.54–2.69)

0.652

  USA300

4 (22 %)

25 (44 %)

0.40 (0.13–1.21)

0.104

0.66 (0.29–1.51)

0.323

  Other

3 (17 %)

7 (12 %)

1.40 (0.41–4.85)

0.594

1.57 (0.48–5.16)

0.458

  1. IQR interquartile range, SCCmec staphylococcal cassette chromosome mec, agr accessory gene regulator, PFGE pulsed-field gel electrophoresis, hVISA heterogeneous vancomycin-intermediate S. aureus
  2. aDefined as death occurring within the first 30 days after the day when the first MRSA positive respiratory or blood culture was collected
  3. bDefined as the day the first MRSA positive respiratory or blood culture was collected until the day the patient was either discharged from the hospital or died
Back to article page

Antimicrobial Resistance & Infection Control

ISSN: 2047-2994

Contact us